Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{171975,
        author = {Fahmia Feroz and Zahoor Ahmad Qazi and Syed Yunis Bukhari},
        title = {An Investigation into Blood-related Disorders in Individuals Diagnosed with Systemic Lupus Erythematosus (SLE).},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {8},
        pages = {1783-1789},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=171975},
        abstract = {Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disorder characterized by widespread inflammation and tissue damage, which can affect various organs, including the skin, kidneys, joints, and hematological system. Hematological complications are common in SLE patients and often play a critical role in disease management and prognosis. These complications include anemia, thrombocytopenia, leukopenia, lymphopenia, and the presence of antiphospholipid antibodies, which contribute to an increased risk of thromboembolic events. The aim of this study is to explore the frequency, types, and clinical implications of hematological disorders in SLE patients, as well as the association between these complications and overall disease activity. A retrospective analysis was conducted using clinical records and laboratory data from a cohort of SLE patients to identify the most prevalent blood-related complications and examine their correlation with disease severity, medication use, and long-term outcomes. The findings of this investigation suggest that hematological abnormalities are not only common in SLE but also significantly affect patient management and quality of life. Anemia, for example, is frequently observed and can result from a combination of chronic inflammation, iron deficiency, and renal dysfunction. Thrombocytopenia and leukopenia, on the other hand, may indicate active disease or side effects of immunosuppressive therapies. Additionally, the presence of lupus anticoagulant and antiphospholipid antibodies increases the risk of thrombosis, which complicates the treatment and management strategies for SLE patients. Understanding the nature and impact of hematological complications in SLE is crucial for the development of personalized treatment plans that address both the underlying disease and associated hematologic abnormalities. This study underscores the importance of comprehensive monitoring and early intervention to optimize clinical outcomes and improve the overall quality of life for patients living with SLE.},
        keywords = {Systemic lupus erythematosus (SLE), thrombocytopenia, leukopenia, lymphopenia, antiphospholipid antibodies, renal dysfunction, immunosuppressive therapies},
        month = {January},
        }